NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $70.91 -2.77 (-3.76%) Closing price 04:00 PM EasternExtended Trading$72.10 +1.20 (+1.69%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytokinetics Stock (NASDAQ:CYTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytokinetics alerts:Sign Up Key Stats Today's Range$70.30▼$73.6350-Day Range$59.58▼$78.7752-Week Range$30.81▼$80.20Volume1.49 million shsAverage Volume2.19 million shsMarket Capitalization$8.82 billionP/E RatioN/ADividend YieldN/APrice Target$99.30Consensus RatingModerate Buy Company Overview Cytokinetics, Inc. is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need. The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility. In parallel, Cytokinetics has advanced reldesemtiv, a skeletal muscle activator, into clinical development for neuromuscular disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy. A third key program, apitegromab, seeks to preserve and restore muscle function in patients with muscle‐wasting diseases by inhibiting myostatin activation. Beyond these lead assets, Cytokinetics maintains a pipeline of early‐stage candidates targeting both cardiac and skeletal muscle biology. While based in the United States, Cytokinetics conducts clinical trials across North America, Europe and Asia, and has forged strategic collaborations with major biopharmaceutical firms to support global development and commercialization. Led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs, the company continues to expand its scientific platform and pursue strategic partnerships. Through its targeted approach to muscle biology, Cytokinetics seeks to bring new therapeutic options to patients suffering from debilitating cardiac and neuromuscular diseases.AI Generated. May Contain Errors. Read More Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCYTK MarketRank™: Cytokinetics scored higher than 56% of companies evaluated by MarketBeat, and ranked 459th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 16 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCytokinetics has a consensus price target of $99.30, representing about 40.0% upside from its current price of $70.91.Amount of Analyst CoverageCytokinetics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($6.27) to ($4.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -10.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -10.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.58% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cytokinetics has recently increased by 3.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.15 News SentimentCytokinetics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 14 articles on an average week.Search InterestOnly 4 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,578,616.00 in company stock.Percentage Held by Insiders2.60% of the stock of Cytokinetics is held by insiders.Percentage Held by InstitutionsCytokinetics has minimal institutional ownership at this time.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYTK Stock News HeadlinesEdward Md Kaye Sells 2,933 Shares of Cytokinetics (NASDAQ:CYTK) StockJune 2 at 4:58 AM | insidertrades.comCytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in GermanyJune 1 at 7:30 AM | globenewswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 2 at 1:00 AM | Porter & Company (Ad)Citi Calls Cytokinetics, Incorporated (CYTK) a “Top Pick” Among Small-to-Mid Cap Biotech StocksMay 29, 2026 | finance.yahoo.comCytokinetics, Incorporated (CYTK) Shareholder/Analyst Call Prepared Remarks TranscriptMay 27, 2026 | seekingalpha.comCytokinetics to Participate in June Investor ConferencesMay 27, 2026 | globenewswire.comFady Ibraham Malik Sells 3,500 Shares of Cytokinetics (NASDAQ:CYTK) StockMay 6, 2026 | insidertrades.comInsider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 15,857 Shares of StockMay 5, 2026 | insidertrades.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $63.54 at the beginning of the year. Since then, CYTK stock has increased by 11.6% and is now trading at $70.91. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, meeting the consensus estimate of ($1.67). The company's revenue was up 1112.5% on a year-over-year basis. Read the conference call transcript. Who are Cytokinetics' major shareholders? Top institutional shareholders of Cytokinetics include Principal Financial Group Inc. (0.88%), Pictet Asset Management Holding SA (0.61%), Affinity Asset Advisors LLC (0.56%) and ADAR1 Capital Management LLC (0.51%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, Sung Lee, John T Henderson, Andrew Callos, Wendell Wierenga, Wendall Wierenga, Muna Bhanji, Robert Arthur Harrington, Robert Wong, B Lynne Parshall and Edward M Md Kaye. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE). Company Calendar Last Earnings5/05/2026Today6/02/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CYTK's financial health is in the Green zone, according to TradeSmith. CYTK has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees250Year Founded1998Price Target and Rating Average Price Target for Cytokinetics$99.30 High Price Target$140.00 Low Price Target$56.00 Potential Upside/Downside+40.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($6.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$784.96 million Net Margins-784.02% Pretax Margin-784.02% Return on EquityN/A Return on Assets-52.86% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio4.21 Sales & Book Value Annual Sales$105.82 million Price / Sales83.39 Cash FlowN/A Price / Cash FlowN/A Book Value($5.39) per share Price / Book-13.16Miscellaneous Outstanding Shares124,433,000Free Float121,198,000Market Cap$8.82 billion OptionableOptionable Beta0.42 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CYTK) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredLet's talk about 87% for a minute87% win rate - out of every 100 trades, 87 close as winners. For context, a strong hedge fund hits around 55%,...Trade To Close | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
